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(HCT), HCV is known to be associated with transient hepatitis in the immediate post-transplant period, and a potential
risk factor of veno-occlusive disease (SOS). Very recently, HCV-infected HCT recipients have been shown to be at higher
risk of earlier cirrhosis, leading to greater morbidity and mortality. Long-term survivors after HCT are thus at a high risk
for HCV-related complications and, as a consequence, the treatment of HCV infection becomes critical. We describe here
the potential clinical complications in HCV-infected recipients, in the short, but also the long-term follow-up after HCT.
The pathophysiology of liver ﬁbrosis is discussed as well as the present recommended therapy in this particular population.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Allogeneic Hematopoietic Cell Transplant (HCT) has
now become a widely used therapeutic procedure to cure
patients withmalignant and non-malignant hematological
disorders. Nearly 90% of the patients, who remain recur-
rence-free of their original disease more than 2 years after
theprocedure, are expected tobecome long-termsurvivors,
leading to thousands of cured patients worldwide [1].
Liver complications inﬂuence morbidity and mortal-
ity in patients undergoing HCT. Liver injury is common
early after HCT because of veno-occlusive disease
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relapse [2–4]. Among the long-term complications, cir-
rhosis is an important late complication of HCT [5].
The hepatitis C virus (HCV), identiﬁed in 1989, is an
enveloped Flavivirus with a 9.6 kb single strand RNA
genome [6]. A signiﬁcant proportion of long-term HCV-
infected HCT survivors, primarily contaminated through
blood exposure, develop cirrhosis and hepatocellular car-
cinoma during long-term follow-up [5,7]. Moreover,
HCT recipients showed a higher rate of liver ﬁbrosis pro-
gression as compared with HCV-infected patients who
did not receive a transplant [7]. We describe here the nat-
ural history ofHCV infection in the early period aswell as
during the long-term follow-up afterHCT.Wediscuss the
potential reasons related to the higher ﬁbrosis rate in
transplanted patients and the anti-HCV therapy of this
particular population.2. Blood exposure
Hepatitis C virus (HCV) is a major cause of liver dis-
ease worldwide. HCV is the most common chronic
blood–borne infection in the United States. The Centers
for Disease Control estimated that during the 1980s, anPublished by Elsevier B.V. All rights reserved.
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Although the annual number of new infections has
declined by more than 80% since the 1990s, popula-
tion-based studies indicate that 40% of chronic liver dis-
eases are HCV-related. HCV is transmitted primarily
through blood exposure. However, blood transfusion,
which accounted for a substantial proportion of cases
of HCV infections acquired more than 10 years ago,
rarely accounts for recently acquired infections owing
to systematic screening of blood products for HCV [8–
11].
While the risk of acquiring HCV infection is now
extremely low, it is not uncommon that patients come
to HCT already infected. Moreover, a large group of
long-term stem cell survivors were infected by HCV dur-
ing the 1980s before blood donors were routinely
screened. Indeed, prospective studies of transfusion
recipients in the United States demonstrated that the
rates of post-transfusion hepatitis in the 1970s exceeded
20% [9]. For instance, in Seattle, WA, HCV was detected
after HCT in 113 of 355 (32%) patients in 1987–1988
[5,12]. A recent prospective study of the European
Group for Blood and Marrow Transplantation, which
included patients who received transfusions in the
‘‘postscreening” era, showed that the prevalence of
HCV RNA-positive stem cell transplant recipients was
6.0% [13]. Thus, chronic hepatitis C in long-term survi-
vors remains an important clinical issue.3. HCV diagnosis in the context of HCT
Virological diagnosis of HCV infection has evolved
with time. At the end of the 80s, the ﬁrst-generation
assay that became available was able to detect antibod-
ies against a blood–borne non-A, non-B hepatitis virus
termed HCV [14,15]. The clinical relevance was contro-
versial in the non-transplanted population since unspe-
ciﬁc reactivity can occur with sera in some categories
of patients [16]. The introduction of a second-generation
test and the use of supplementary tests such as RIBA
have improved the reliability of serologic assays. The
clinical relevance of positive HCV antibodies in HCT
patients was still questionable. It has thus been shown
that highly immunosuppressed patients may have a
defect in producing antibody [17,18]. HCT recipients
are usually not able to mount a serologic response to
virus infections during the ﬁrst year after transplant.
Moreover, positive HCV antibodies may be the conse-
quence of passive antibody transfer by transfusion, in
the absence of preceding viremia. Those methods were
largely used as diagnosis in many studies after HCT
leading to under- (lack of speciﬁcity) or over-estimation
(lack of sensibility) of HCV-infected HCT patients. In
the beginning of the 1990s, the direct detection of
HCV by polymerase chain reaction (PCR) allowed toestimate the true frequency of HCV infection in blood
donors [19,20]. As was predictable, studies reported
patients who were PCR-positive and negative by
serologic tests, notably in the period following HCT
[21,22].
Regarding assays to detect HCV antibodies, the spec-
iﬁcity of third generation EIAs is greater than 99% [23].
Their sensitivity is more diﬃcult to determine, given the
lack of a gold standard method, but it is excellent in
HCV-infected immunocompetent patients. HCV-RNA
testing is still helpful in patients with immune depression
clinical or analytical suspicion of liver disease [24,25],
notably after HCT [12].4. HCV-infected HCT recipients and clinical outcome
4.1. Short-term outcome
In the ﬁrst three months after transplant, liver dys-
functions related to HCV are usually mild
[12,22,26,27] limited to 5- to 10-fold increase in ala-
nine aminotransferase (ALT) [22]. Several causes of
liver dysfunctions are present at this time (2–4). The
main problem during this period is to diﬀerentiate
between acute GVHD and hepatitis. Unless there is
evidence of active GVHD in other organs, a liver
biopsy is usually needed before a therapeutic decision
is made. Pathologic distinctions between HCV and
GVHD may be diﬃcult, as both are associated with
portal lymphoid inﬁltration and bile duct injury. Nev-
ertheless, marked bile duct injury with epithelial cell
drop-out and loss of interlobular bile ducts are more
typical of GVHD [12,28,29]. After three months, the
occurrence of late hepatitis is possible, which coincides
with a decrease in or discontinuation of immunosup-
pressive therapy and a return of cellular immunity
[12,13,26,30,31]. The most diﬃcult situation at this
time is the unusual presentation of liver GVHD (hepa-
tic Variant), resembling viral hepatitis [32,33], also
described after donor lymphocyte infusion [34], in
which liver biopsy is essential to conﬁrm GVHD.
4.2. HCV and hepatic sinusoidal obstruction syndrome
(SOS)
Veno-occlusive disease has been recently renamed
hepatic sinusoidal obstruction syndrome (SOS) [35,36].
SOS is a liver toxicity syndrome after BMT caused by
occlusion of centrilobular venules and damage to the
surrounding hepatocytes and sinusoids, after myeloabla-
tive conditioning regimen [36,37]. SOS of the liver is
characterized by hyperbilirubinemia, ﬂuid retention,
and painful hepatomegaly appearing soon after BMT
[36,38]. Individual variability in cyclophosphamide
metabolism, total body irradiation (TBI) dose, use of
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mation and ﬁbrosis are risk factors [12,39–41].
The potential role of HCV in the development of SOS
remained for a long time a matter of debate in the liter-
ature, as illustrated in the Table 1. The role of HCV a
risk factor for fatal SOS was identiﬁed in a cohort of
patients who received cyclophosphamide or TBI over
12 Gray, related to sinusoidal toxins of those regimens.
HCV is thus not considered as a risk factor if the condi-
tioning regimen has little or no liver toxicity such as ﬂu-
darabine and targeted busulfan [42,43] or non-
myeloablative regimen of ﬂudarabine plus low-dose
TBI [44]. An informative review on management of
hepatic disease following haematopoietic cell transplant
has been published recently [45].
4.3. Long-term outcome (Table 2)
For a long time, HCV infection was not considered
as a major problem after HCT. Studies appeared con-
comitantly demonstrating the ability to identify anti-
bodies directed against HCV [14,15]. In 1991,
Locasciulli et al. found an overall prevalence of posi-
tive HCV antibodies of 28.6% (38/128 patients) which
was not correlated with more severe liver disease after
HCT. Nevertheless, pathological ﬁndings demon-
strated more severe liver damage in patients with
HCV-positive antibodies. A chronic hepatitis was thus
diagnosed in 9 out of 11 patients presenting antibodies
against HCV while in only one patient out of 7 who
did not have positive HCV antibodies [46]. Further
studies were more attentive to the risk of acquiring
HCV infection in the context of HCT than to deter-
mine the role of HCV in post-transplant liver compli-
cations [47–49]. Moreover, Norol et al. showed that
HCV-positive antibodies before and after HCT were
not predictive of SOS, liver GVHD, or death due to
liver dysfunction. In contrast, the risk of chronic hep-
atitis was signiﬁcantly increased [49]. The ﬁrst study
which directly assessed the impact of HCV infection
in long-term survivors after HCT was conducted by
Ljungman et al. [22]. The diagnosis was based onTable 1
HCV and the risk of SOS
Sources Year HCV-infected patients#
Frickhofen et al. 1994 (retrospective) 6/61
Ljungman P et al. 1995 (prospective) 10/161
Rodriguez-Inigo E et al. 1997 (prospective) 11/58
Locasciulli et al. (EBMT) 1999 (prospective) 11/193
Strasser et al. 1999 (prospective) 62/355
Abbreviations: #Number of HCV-infected patients before transplant versus to
versus number of SOS among HCV-negative recipients. *Three patients were
during or shortly after BMT. ***One patient was infected during or shortly aft
*****Fifty-two patients developed HCV infection during the HCT process; othe HCV positivity either by PCR for HCV-RNA or
by second-generation enzyme-linked immunoabsorbent
assay (ELISA) and RIBA or EIA supplemental assay.
Of 161 surviving patients transplanted between 1978
and 1991, 28 (17.4%) were found to have chronic
HCV infection. No signs of severe progressive liver
disease were shown among the patients included in
this study with a follow-up median time of 6.1 years
[22]. Thomas et al. with an average follow-up of 6
years found no evidence of cirrhosis [50]. In 1999,
the Seattle group reported a cohort of 355 patients
that underwent HCT between 1987 and 1988 from
which 113 (32%) were HCV RNA-positive by day
100 post-transplant. During 10 years of follow-up,
no patients developed clinical evidence of liver disease,
and HCV infection did not impact the actuarial sur-
vival of long-term survivors over this time period
[12]. It was thus concluded that HCV infection was
not associated with excess mortality over ten years
of follow-up.
However, the same group observed the development
of cirrhosis leading to hepatic decompensation and
hepatocellular carcinoma in HCV-infected, marrow
transplant recipients, surviving beyond 10 years. Among
3721 patients who survived 1 or more years after HCT,
31 developed cirrhosis. Cirrhosis was attributed to HCV
in 15 of 16 patients presenting more than 10 years after
HCT [5]. In our experience, 15 patients among 96 HCT,
HCV-infected recipients (diagnosed by RT-PCR), devel-
oped biopsy-proven cirrhosis at a median follow-up of
15.7 years, leading to a cumulative incidence of cirrhosis
of 24% at 20 years. HCV infection ranked third, behind
infection and GVHD, as a cause of late death. More-
over, cirrhosis was diagnosed beyond 10 years after
transplantation in 13 of our 15 patients. We thus
observed 3 cases of hepatocellular carcinoma [7]. Ivantes
et al. also found cirrhosis on a smaller group of patients
followed up more than ten years after HCT [51]. Thus,
HCT recipients with HCV infection present a higher risk
of earlier cirrhosis.
HCT, HCV-infected patients thus present a higher
risk of earlier cirrhosis in the long-term follow-up.SOS after transplant§ HCV as a SOS risk factor
5/6 versus 9/52* Yes (p < 0.005)
1/10 versus 12/133** Non-signiﬁcant
2/11 versus 7/46*** Non-signiﬁcant
1/11 versus 15/170**** Non-signiﬁcant
22/46 evaluable
patients versus 32/229*****
p < 10–3 if associated with elevated
AST before transplant
tal number of patients. §Number of SOS among HCV-infected patients
infected during or shortly after BMT. **Eighteen patients were infected
er BMT. ****Twelve patients were infected during or shortly after BMT.
nly severe SOS is depicted.
HCV
BMT
Incidence of Cirrhosis in
Bone marrow transplanted patients  (n = 96) 
In non transplanted mono-infected HCV (n = 290)
0.2
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Fig. 1. Cumulative incidences of cirrhosis in chronic hepatitis C patients
with stem cell transplant compared to HCV-infected patients without
transplantation. Stem cell transplant recipients with chronic hepatitis C
(n = 96) had an expected median time to cirrhosis of 18 years as
compared with 40 years in the control chronic hepatitis C population
without transplants (n = 290). Ref. [7].
Table 2
Retrospective analysis of HCV infection in the long-term follow-up after HCT
Sources Year Number of
HCV patients
HCV diagnosis Median follow-up
(years)
HCV-related complications
Locasciulli et al. [46] 1991 38/128 Serology 2 Hepatitis exacerbation after HCT
More severe liver damage (biopsy) in
anti-HCV+ patients
Norol et al. [49] 1994 14/120 Serology Not given More chronic liver disease in HCV+ patients
Ljungman et al. [22] 1995 28/161 Serology and PCR 6.1 No diﬀerence according to HCV status
Strasser et al. [12] 1999 113/355 PCR 10.4 No diﬀerence according to HCV status
Thomas et al. [50] 2000 29/61* Serology and PCR 6 No increase of morbidity or mortality
Peﬀault de Latour et al. [7] 2004 96/686 PCR 15.7 Fifteen patients with biopsy-proven cirrhosis
Ivantes et al. [43] 2004 31/80 Serology and PCR Patients studied
were alive at least
10 years after HCT
Three cirrhosis within the 22 HCV
patients studied
*The total number of patients is 106 with 61 patients who had chronic liver disease.
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5.1. Fibrosis progression in non- transplanted HCV-
infected patients
Liver ﬁbrosis is the excessive accumulation of extra-
cellular matrix proteins including collagen [52,53].
Fibrogenesis is a complex dynamic process, which is
mediated by necroinﬂammation and activation of stel-
late cells. Liver molecular markers (matrix turnover,
cytokines) have been associated with ﬁbrosis progres-
sion [54]. The severity of disease varies widely from
asymptomatic chronic infection to cirrhosis and hepato-
cellular carcinoma. The natural history of liver ﬁbrosis is
inﬂuenced by both genetic and environmental factors
[55]. The major factors known to be associated with
ﬁbrosis progression are male gender, older age at infec-
tion, and excessive alcohol consumption. Hepatic stea-
tosis, obesity, and diabetes may also contribute to
more rapid progression of ﬁbrosis [56]. Cryoglobuline-
mia has also been associated with ﬁbrosis in chronic
hepatitis C [57].
5.2. Fibrosis progression after HCT
We observed in a study on 96 HCV-infected HCT
patients with a median follow-up of 15.7 years a more
rapid rate of liver ﬁbrosis progression in transplanted
patients as compared with HCV-infected non-trans-
planted patients (Fig. 1). All these patients had antibodies
against HCV and detectable serum HCV-RNA. The
expected median time to cirrhosis in allogeneic bone mar-
row transplant recipients was about 18 years as compared
with 40 years in the control population [7]. Another study
also conﬁrmed the higher rate of ﬁbrosis progression in
HCT recipients. For the three cirrhotic patients of this last
study, the average time betweenHCTanddevelopment of
cirrhosis was 13 years [51]. These data coming from retro-
spective studies, should be considered cautiously.The classic understanding of the pathogenesis of liver
disease is that it is due to the cellular immune response
against the virus, speciﬁcally that of cytotoxic T lym-
phocytes, which activates hepatic stellate cells, and, thus
leads to liver inﬂammation and ﬁbrosis. The possible
high rate of liver ﬁbrosis after HCT, as well as other
patients with depressed cellular immunity (HIV co-
infection [58,59] and HCV-infected solid organ trans-
plant recipients [60–63], raises fundamental questions
about the pathogenesis of liver injury. If there is a more
rapid disease progression, it could suggest that, although
some aspects of the immune cellular response are clearly
ineﬀective at clearing virus, they do serve to limit liver
damage [64]. The HST population has no liver ﬁbrosis
progression risk factors since they were young at the
onset of infection and have not consumed alcohol. The
viral load does not seem to inﬂuence the liver ﬁbrosis
in immunocompetent patients but a role is suspected
in ﬁbrosis progression in HIV/HCV-co infected patients
[65]. The HCV viral load is thus higher (up to 10 times)
in immunocompromised patients [66,67]. Maina et al.
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immediate period of post-liver transplantation is predic-
tive of more advanced liver disease during the follow-up
[68].
In our study, we combined the two patient popula-
tions (with and without transplants) and analyzed the
risk factors for developing cirrhosis. Only HCT emerged
as a signiﬁcant risk factor by multivariate analysis [7].
Many factors favour liver ﬁbrosis during HCT
(Fig. 2). Before transplant, the conditioning alone may
support the liver injury, notably TNFa, inﬂammatory
cytokines known to increase liver ﬁbrosis [69]. Iron over-
load is frequent after HCT, ﬁrst, because of up-regula-
tion of intestinal iron transport, and second, because
of transfusions [70]. Iron overload and HCV infection
are independent risk factors for liver ﬁbrosis progres-
sion, and their concomitant presence results in a striking
increase in risk [71]. Insulin resistance, steatosis and/or
obesity are now recognized as important risk factors
for ﬁbrosis progression [56,72]. Diabetes and steatosis
induced by steroids and parenteral nutrition after
HCT may explain this observation. In the immediate
post-transplant period, the donor response is limited
because of immunosuppressive treatment. The HCVFig. 2. Physiopathology of liver lesions in Stem cell transplant recipients with
immunosuppressed context that are responsible for quicker ﬁbrosis progression
liver injury, as well as inﬂammatory cytokines. Iron overload (transfusions) is
HCV replication rate exceeds largely the kinetics of the immune response. T
resistance, steatosis and/or obesity are now recognized as important risk for
recover after transplant. HCV is able to inhibit NK cell cytotoxicity and cytokin
after HCT. Reconstitution of the immune system after a period of depressed ce
enhanced HCV-speciﬁc immune responses. Long-term outcome: a more rapid ra
with an expected median time to cirrhosis of about 18 years after HCT.replication rate exceeds largely the kinetics of the
immune response such that the eﬀector-to-target cell
ratio favours the virus. The HCV virus load is upper
the observed level in HCV-infected non-transplanted
patients (data not shown). The virus extension is rapid
to a high number of hepatocytes. NK compartment is
the ﬁrst to recover after transplant [73]. It has recently
been shown that high concentration of recombinant
HCV N2 inhibits their cytotoxicity and cytokine pro-
duction [74,75], as it could be the case after HCT. Reg-
ulatory T cells are able to protect mice from GVHD [76].
Their potential role is still discussed in humans [77]. It
was recently shown that a high proportion of the cellular
inﬁltrate in persistent HCV infection includes FOXP3-
positive cells [78]. We can hypothesize that Regulatory
T cells are able to inhibit the immune response after
HCT and favour chronic liver disease. Speciﬁc humoral
immune response takes time and is limited after HCT
[73]. Reconstitution of the immune system after a period
of depressed cellular immune responses increases inﬂam-
matory activity in the liver, with enhanced HCV-speciﬁc
immune responses [27]. Moreover, in chronic HCV
patients, ALT elevation is more frequent, severe and
protracted following HCT compared to autologouschronic hepatitis C. There are speciﬁc factors due to the allogeneic and
: Pre-transplant liver toxicity: the conditioning may directly support the
also responsible for liver ﬁbrosis. Immediate post-transplant period: the
he virus extension is rapid to a high number of hepatocytes. Insulino
ﬁbrosis progression. Immune recovery: NK compartment is the ﬁrst to
e production. Speciﬁc humoral immune response takes time and is limited
llular immune responses increases inﬂammatory activity in the liver, with
te of liver ﬁbrosis progression is observed in HCV-infected HCT patients
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enhance the immune response. Many unanswered ques-
tions thus remain in the context of HCT and there is a
need for large prospective studies on this speciﬁc popu-
lation to elucidate the diﬀerent steps for ﬁbrosis
progression.6. Treatment
6.1. HCV therapy in non-transplanted HCV-infected
patients
The primary aim of treatment is viral eradication,
resulting in cure of infection [80–83]. The other aim is
to prevent, stabilize, or obtain regression of ﬁbrosis.
To date, in a patient with HCV, combined therapy asso-
ciating pegylated alpha interferon and ribavirin results
in a sustained virological response in approximately
55% of cases [84,85]. In these two studies, the sustained
virological response was approximately 80% in genotype
2 or 3 infection a with 24-week treatment duration and
50% in genotype 1 with a 48-week duration. Based on
existing results, the sustained virological response with
this treatment option appears to be long-lasting, to be
associated with a histological beneﬁt and is also proba-
bly associated with a reduction in the risk of cirrhosis
and hepatocellular carcinoma. The pre-therapeutic pre-
dictive factors of eﬃcacy of treatment are mainly linked
to the virus (genotype non-1 and low viral load) and less
to the patient (female sex, younger age, less severe liver
disease, minimal or moderate ﬁbrosis) [84,85].
6.2. HCV therapy HCV-infected HCT patients
Unfortunately, little has been published speciﬁcally
concerning the treatment of HCV-infected SCT recipi-
ents. During the transplant period, RBV has been used
to prevent immediate liver disease by HCV [86]. How-
ever, only one study reported the eﬀects of standard
IFN therapy in SCT recipients with only 10 patients
completing the protocol, of whom ﬁve responded to
treatment [87]. Four of these ﬁve patients had persis-
tently undetectable HCV-RNA. We recently described
our experience in the treatment of these patients. We
were able to treat only 22 of 36 SCT recipients who
needed anti-HCV therapy because of liver disease (mod-
erate to advanced ﬁbrosis) but who also had treatment
contraindications. We obtained a sustained virological
response in 6 out of 22 patients (27%), 4 of whom were
treated with combination therapy. Although only a few
patients were treated, the combination treatment seemed
more eﬀective in achieving sustained virological
response. However, the combination therapy also
resulted in more hematological complications. While
anemia could be easily managed with dose modiﬁcationand/or erythropoietin, thrombocytopenia mostly led to
treatment interruption [88]. It is noteworthy that no
IFN treatments induced or precipitated GVHD.
Those results are in accordance with what is observed
in other immunocompromised individuals. HCV treat-
ment is thus often associated with a poor response.
Among 106 patients co-infected with HIV/HCV, only
16% had a sustained virological response mainly because
of discontinuation due to adverse events [89]. In liver
transplantation, PEG IFN and RBV treatments
achieved virological response in 9 out of 20 patients
(45%). Treatment was withdrawn in four patients
(20%) and the dose of PEG IFN and of RBV was
reduced for six and 13 patients, respectively [90]. These
results have been conﬁrmed recently [91].
In clinical practice, liver biopsy should be performed
to evaluate precisely the severity of liver disease (ﬁbrosis,
necroinﬂammantion), determine its prognosis and direct
the choice of the therapeutic options. Combination ther-
apy with pegylated interferon and ribavirin could be rec-
ommended for this particular population, in patients
with moderate to advanced ﬁbrosis. The literature
emphasizes the diﬃculty in obtaining a sustained viro-
logical response in such patients, mainly because of
treatment discontinuation due to adverse events, and
also partly because of diﬃculty in attaining a strong
immune response [92]. Treatment eﬃcacy seems to
increase if treatment is begun at an optimal dose with
close follow-up so that the doses can be rapidly modiﬁed
to avoid stopping treatment. Good compliance to treat-
ment is essential. Potential psychological disturbances
should be anticipated (depression). Undesirable side
eﬀects that might require lowering doses should be rap-
idly identiﬁed. In our experience, the use of growth fac-
tors and erythropoietin enabled continuation of the
treatment in some cases. New drugs, such as viral
enzyme inhibitors (proteases and polymerases), are
expected to improve the eﬃcacy of HCV therapy in
the near future [93–95].
6.3. Guidelines in the context of HCT
Concerning the donor, in case of HCV infection, an
alternate donor should be considered if available. If
there is no other donor, HCT is not contraindicated
because of HCV infection. First, a speciﬁc treatment
of the donor is possible before marrow or stem cell
harvest allowing a HCV-negative sampling [96,97].
Second, acquiring HCV during transplant from an
HLA-matched but HCV-infected donor is associated
with low morbidity in the subsequent 10 years com-
pared to a less well matched HCV-negative donor.
Third, we have to keep in mind the major risk of
relapse in case of hematological disease and that most
of the time it will not allow HCV treatment of the
donor before HCT.
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plant, active liver disease or cirrhosis should be assessed
by biopsy. It is recommended to treat the patient before
the stem cell infusion in view of the risk of the hemato-
logical disease. At the time of transplant, prevention of
sinusoidal injury is fundamental in case of advance
chronic liver disease, portal hypertension or cirrhosis.
The actual recommendation is to use a sinusoidal
toxin-free regimen, such as non-myeloablative condi-
tioning [44], if such a regimen is not worse in terms of
anti-tumor activity and, of course, if the patient does
not present any other co-morbidity [98]. After trans-
plant, patients should be evaluated for the development
of chronic hepatitis (clinic and liver biopsy), and also
because of the unusual hepatic variant GVHD presenta-
tion that needs urgent treatment. The patients who
showed ﬁbrosis progression should be treated if they
do not have on-going chronic GVHD and/or an inten-
sive immunosuppressive therapy.7. Conclusion
While the risk of acquiring HCV infection is now
extremely low, it is not uncommon for patients to come
to HCT already infected. Pre-existing HCV infection
seems to be associated with an increased risk of severe
SOS [5,99,100] but the immediate post-transplant period
is rarely a problem. The long-term follow-up has been
recently shown to be associated with an increased risk
of earlier cirrhosis compared with HCV-infected non-
transplanted patients. The rate of ﬁbrosis progression is
higher in HCV-infected HCT recipients than in the
non-transplanted control group, which is in accordance
with what is observed in other immunocompromised
patients [59–63]. Histological liver evaluation should be
performed in all patients after HCT to evaluate the stage
of ﬁbrosis and grade of necroinﬂammation. In candidates
for HCV therapy, patients may beneﬁt from combined
PEG IFN and RBV treatment in the absence of chronic
GVHD and/or an intensive immunosuppressive therapy.
This treatment clearly needs close clinical and biological
monitoring to prevent side eﬀects in this particular
population.
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